But clinical trials says the predetermined secondary endpoint was ITT population and that was 23.3 months vs. 18.9 months (p=0.0511) BUT the final analysis says 23.3 vs. 18.9 (p=0.0494) https://t.co/N9BVAOHNyw
4,206 followers
1,208 followers
New 3i Investigator Article Alert!! Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. https://t.co/MA6A9ihcc8 #sciencetwitter #a
438 followers
RT @sitcancer: #JITC Short Report: Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-mac…
19,075 followers
#JITC Short Report: Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma https://t.co/E3OCjzEn2m https://t.co/iXRhZM6pio